• Lineage Provides Update on OpRegen Clinical Study americanpharmaceuticalreview
    January 06, 2020
    Lineage Cell Therapeutics announced additional patient data from its ongoing Phase I/IIa clinical study of OpRegen®, the Company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (dry AMD) ...
PharmaSources Customer Service